and the second



DTC Dec'd PCT/PTO 23 DEC 2007

FORM PTO-1390 U.S. DEI (REV. 10-2003)	ATTORNEY'S DOCKET NUMBER								
TRANSMITTAL LETTER	1718-Ö218PUS1								
DESIGNATED/ELECTE	D OFFICE (DO/EO/US)	U.S. APPLICATION NO. (ILL nown, see 37 CFR 1.5)							
CONCERNING A FILING UNDER 35 U.S.C. 371									
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED							
PCT/SE2003/001100	June -24, 2003	June 27, 2002							
TITLE OF INVENTION Synergistic Interaction of Abacavir and Alovudine									
APPLICANT(S) FOR DO/EO/US Goran MARDH									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
 This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 									
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include									
items (5), (6), (9) and (21) indicated below.									
4. The US has been elected (Article 31).									
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))									
a. is attached hereto (required only if not transmitted by the International Bureau). WO/2004/002433 A12									
b. has been communicated by the International Bureau.									
c. is not required, as the application was filed in the United States Receiving Office (RO/US).									
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).									
a. is attached hereto.									
b. has been previously submitted under 35 U.S.C. 154(d)(4) 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).									
a. are attached hereto (required only if not communicated by the International Bureau).									
b. have been communicated by the International Bureau.									
_									
d. A have not been made and will not be made.									
8. An English language translation of the	ne amendments to the claims under PCT Articl	le 19 (35 U.S.C. 371(c)(3)).							
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).									
a is attached hereto.									
b. has been submitted to the Internal Bureau (See Box VIII-4-1 of the Request (PCT/R0/101), copy attached).									
The Power of Attorney or Authorization of Agent and Certificate under 37 CFR 3.73(b) Showing Chain of Title are: attached hereto. will follow.									
	Title are: attached hereto will follow. 10 An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36								
(35 U.S.C. 371(c)(5)).									
Items 11. to 20. below concern document(s) or information included:									
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98, Form PTO-1449(s), and International Search Report (PCT/ISA/210) with 0 cited document(s).									
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.									
13. A preliminary amendment.									
14. An Application Data Sheet									
15. A substitute specification.									
16. A power of attorney and/or change of address letter.									
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.									
18. A second copy of the published international application under 35 U.S.C. 154(d)(4).									
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. Other items or information:									
Express Mailing Certificate (Label No. EV 592977178 US)									
Formal Drawings - Three (3)									

U.S. APPLICATION NO (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO				ATTORNEY'S DOCKET NUMBER			
1 (1E)	PCT/SE2003/001100				1718-0218PUS1		
21. The following fees are submitted:					CAL	CULATIONS	PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO Basic National Stage Fee							
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$950.00							
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$790.00							
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$750.00							
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)\$100.00					\$	1000.00	#
ENTER APPROPRIATE BASIC FEE AMOUNT =					Ļ	1000.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).					\$	130.00	
SHEETS OF SPEC & DWG	14 -100 = 0		0 x 250 =	\$0	\$	0.00	
CLAIMS	NUMBER FILI	ED	NUMBER EXTRA	RATE			
Total Claims	12 - 20 =		0	x \$50.00	\$	0.00	
Independent Claims	3 - 3 =		0	x \$200.00	\$	0.00	
MULTIPLE DEPEND	ENT CLAIM(S) (if ap	plicable))	+ \$360.00	\$		
TOTAL OF ABOVE CALCULATIONS =					\$	1130.00	
Applicant claims small entity status. See 37 C.F.R. § 1.27. The fees indicated above are reduced by 1/2.					\$		
SUBTOTAL =					\$	1130.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)).					\$		
TOTAL NATIONAL FEE =					\$		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					\$		
TOTAL FEES ENCLOSED =					\$	1130.00	
						Amount to be: refunded	\$
						charged	\$
		-			<u> </u>	chargeu	Ψ
a. A check in the	e amount of \$0.00 to c	over the	above fees is enclosed.				
b. Please charge this sheet is er		No. 02-2	2448 in the amount of \$1,1	30.00 to cove	r the al	oove fees. A du	plicate copy of
	ioner is hereby author unt No. 02-2448.	ized to cl	harge any additional fees t	hat may be re	quired,	or credit any o	verpayment to
			C.F.R. § 1.495 has not be the application to pend		etition	to revive (37 C	C.F.R. § 1.137(a)
Send all correspondence to: Birch, Stewart, K P.O. Box 747	olasch & Birch, LLP	or Cus	stomer No. 02292	-		1	
Falls Church, VA	22040-0747						
(703) 205-8000					1.1.	.//	
Date: <u>December 23</u>	3, 2004			B		inso_	
/sbp				Leona	ırd R. S	Svensson, #30,3	30
Ē							

MS PCT
PATENT
1718-0218PUS1

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

Goran MARDH

Conf.:

Appl. No.:

NEW

Group:

Filed:

December 23, 2004

Examiner: UNASSIGNED

For:

SYNERGISTIC INTERACTION OF AVACAVIR AND

ALOVUDINE

EXPRESS MAIL CERTIFICATE

DATE DEPOSITED:

December 23, 2004

I hereby certify that the enclosed TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING ORDER UNDER 35 U.S.C. 371 AND RELATED DOCUMENTS is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Express Mail Label No.: EV 592977178 US

Date: December 23, 2004

andra Br Paul

Mailing Address:

BIRCH, STEWART, KOLASCH & BIRCH, LLP P.O. Box 747 Falls Church, VA 22040-0747 (703) 205-8000